Recombinant interferon-α2B efficacy in complex therapy of pneumonia in premature newbornsA prospective randomized study of clinical efficacy of
recombinant interferon-α
2b in combination
Interferon alpha-2b treatment for exophytic nasal papillomas and human papillomavirus infection with
recombinant interferon and
a reduction in the recurrence rate of ESP. Conclusion: According to the results
Recombinant interferon-a2b efficacy in complex therapy of pneumonia in premature newbornsA prospective randomized study of clinical efficacy of
recombinant interferon-a2b in combination
Different Kinds of Interferon-Corrective Therapy in Congenital and Acquired Interferonopathies is performed. In both replacement and
interferon-corrective therapies
recombinant human IFN alpha
2b VIFERON (R
The value of interferon therapy for COVID-19 in children in the immunopathogenesis of COVID-19 and the clinical efficacy of drugs based on
recombinant interferon-alpha
2b OBTAINING SINGLE DOMAIN NANOBODIES SPECIFIC FOR HUMAN INTERFERON-β AND THEIR USE IN AFFINITY PURIFICATION is paid to obtaining nanobodies specific for human
interferon-β in order to obtain
a preparation with high
Clinico-immunological effectiveness of immunotherapy in patients with respiratory syncytial virus infection (bronchitis, acute tonsillitis, pneumonia). 29 patients were treated by
recombinant interferon-α
2b in the form